Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy

被引:5
|
作者
Fang, Rui [1 ,2 ]
Wang, Heng [1 ,2 ]
Li, Yang [1 ,2 ]
Liu, Yue-Ming [1 ,2 ]
Wei, Wen-Bin [1 ,2 ,3 ,4 ,5 ,6 ]
机构
[1] Beijing Tongren Hosp, Beijing 100730, Peoples R China
[2] Capital Med Univ, Beijing 100730, Peoples R China
[3] Beijing Tongren Eye Ctr, Beijing, Peoples R China
[4] Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing, Peoples R China
[5] Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China
[6] Minist Ind & Informat Technol, Med Artificial Intelligence Res & Verificat Lab, Beijing, Peoples R China
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
Uveal melanoma; Plaque radiotherapy; Tumor regression; Prognosis; CHOROIDAL MELANOMAS;
D O I
10.1186/s12886-021-01898-3
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background Tumor regression of uveal melanomas (UMs) after radiotherapy has been reported as a valuable prognostic factor for metastasis and metastatic death. But its effect on prognosis is questionable. The purpose of this study was to summarize the regression features of uveal melanoma after iodine-125 plaque brachytherapy and the relationship with prognosis. Methods Adult uveal melanoma patients who only received iodine-125 plaque brachytherapy between December 2009 and March 2018 at the Beijing Tongren Hospital, Capital Medical University were enrolled in this study. The regression rate was calculated as the percent change in tumor height, and each eye was classified for four main regression patterns: Decrease (D), Stable (S), Others (O), and Increase (I), according to the trend of height change. Statistical analysis was performed using one-way ANOVA and chi-square test, univariate and multivariate logistic regression, and Kaplan-Meier analysis. Results A total of 139 patients was included in the study. The median follow-up was 35 months. Regression patterns status was pattern D in 65 tumors (46.8%), pattern S in 50 tumors (36.0%), pattern O in 6 tumors (4.3%), and pattern I in 18 tumors (12.9%). Reductions of tumor mean height for each follow-up visit were 5.26% (3 months), 10.66% (6 months), 9.37% (12 months), and 14.68% (18 months). A comparison (D vs. S vs. O vs. I) revealed the preoperative height of pattern I was significantly lower than the pattern D, S and O (mean: 7.24 vs. 7.30 vs. 6.77 vs. 5.09 mm, respectively; P = 0.037). LBD (largest basal diameter) was strongly associated with the metastasis (P = 0.03). However, an association between the tumor regression and subsequent melanoma-related metastasis and mortality could not be confirmed (P = 0.66 and P = 0.27, respectively). The tumor regression rate increased with increasing tumor height (P = 0.04) and decreased with increasing of LBD (P = 0.01). Conclusion Our study showed a lack of association between the prognosis and the regression of uveal melanomas following I-125 plaque radiotherapy. The LBD and original height of the tumor have predictive value in tumor regression rate, and LBD was positively associated with metastasis.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy
    Rui Fang
    Heng Wang
    Yang Li
    Yue-Ming Liu
    Wen-Bin Wei
    BMC Ophthalmology, 21
  • [2] Glaucoma in Patients After Iodine-125 Brachytherapy for Uveal Melanoma
    Hung, Crystal
    McCannel, Tara
    Law, Simon
    Giaconi, JoAnn
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [3] Iodine-125 episcleral plaque therapy in uveal melanoma
    Sia, S
    Harper, C
    McAllister, I
    Perry, A
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2000, 28 (06): : 409 - 413
  • [4] Glaucoma After Iodine-125 Brachytherapy for Uveal Melanoma: Incidence and Risk Factors
    Kim, Eun-Ah
    Salazar, Diana
    McCannel, Colin A.
    Kamrava, Mitchell
    Demanes, David J.
    Lamb, James
    Caprioli, Joseph
    McCannel, Tara A.
    JOURNAL OF GLAUCOMA, 2020, 29 (01) : 1 - 10
  • [5] Visual outcomes and eye preservation after iodine-125 brachytherapy for uveal melanoma
    Blurton, AF
    De La Garza, A
    McCoy, T
    Ekstrand, K
    Greven, C
    Greven, K
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S159 - S159
  • [6] Glaucoma after Iodine-125 Brachytherapy for Uveal Melanoma: Incidence and Risk Factors
    Kim, Eun-Ah
    Kamrava, Mitchell
    Lamb, James
    Caprioli, Joseph
    McCannel, Tara A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [7] Possible Effects of The Extent of Exudative Retinal Detachment on the Regression of Posterior Uveal Melanoma Following Iodine-125 Plaque Brachytherapy
    Kiratli, Hayyam
    Bilgic, Sevgal
    Gedik, Sansal
    Taylan, Hande
    TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, 2005, 35 (03): : 258 - 264
  • [8] Outcomes of Iodine-125 Plaque Brachytherapy for Uveal Melanoma With Intraoperative Ultrasonography and Supplemental Transpupillary Thermotherapy
    Badiyan, Shahed N.
    Rao, Rajesh C.
    Apicelli, Anthony J.
    Acharya, Sahaja
    Verma, Vivek
    Garsa, Adam A.
    DeWees, Todd
    Speirs, Christina K.
    Garcia-Ramirez, Jose
    Esthappan, Jacqueline
    Grigsby, Perry W.
    Harbour, J. William
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (04): : 801 - 805
  • [9] Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5
    Binder, Christina
    Mruthyunjaya, Prithvi
    Schefler, Amy C.
    Seider, Michael I.
    Crilly, Richard
    Hung, Arthur
    Meltsner, Sheridan
    Mowery, Yvonne
    Kirsch, David G.
    Teh, Bin S.
    Jennelle, Richard L. S.
    Studenski, Matthew T.
    Liu, Wu
    Lee, Choonik
    Hayman, James A.
    Kastner, Brian
    Hadsell, Michael
    Skalet, Alison H.
    OCULAR ONCOLOGY AND PATHOLOGY, 2020, 6 (03) : 210 - 218
  • [10] Management of ciliary body melanoma with iodine-125 plaque brachytherapy
    Krema, Hatem
    Simpson, E. Rand
    Pavlin, Charles J.
    Payne, David
    Vasquez, Luz Maria
    McGowan, Hugh
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2009, 44 (04): : 395 - 400